Financings Of The Fortnight: Recent IPO Slowdown Not Necessarily A Harbinger For A Bad 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
Series A financing volume is up in recent years, suggesting that 2014 will be a strong year for biotechs opting to go public. Plus financing news from Atara Biotherapeutics, Crescendo Biologics, Acucela and TetraLogic.